Abstract

Cell homeostasis and regulation of metabolic pathways are ensured by synthesis, proper folding and efficient degradation of a vast amount of proteins. Ubiquitin-proteasome system (UPS) degrades most intracellular proteins and thus, participates in regulation of cellular metabolism. Within the UPS, proteasomes are the elements that perform substrate cleavage. However, the proteasomes in the organism are diverse. Structurally different proteasomes are present not only in different types of cells, but also in a single cell. The reason for proteasome heterogeneity is not fully understood. This review briefly encompasses mammalian proteasome structure and function, and discusses biological relevance of proteasome diversity for a range of important cellular functions including internal and external signaling.

Keywords: Cell biology, Biochemistry, Molecular biology

1. Introduction

Most intracellular proteins are degraded by the ubiquitin-proteasome system (UPS) (Livneh et al., 2016). The proteasomes are multi-subunit protein complexes, responsible for protein breakdown. Thus, they represent central element of the UPS. Accumulating data indicate that cellular proteasome pool is more diverse and flexible than
previously anticipated. A single cell can contain various forms of proteasomes differing by: structural and catalytic subunits; interaction with different regulators; posttranslational modifications of subunits (Dahlmann, 2016; Hirano et al., 2016). The repertoire of proteasome forms is dynamic and changes from tissue to tissue and even from cell to cell, presumably reflecting cellular function, state, condition and ongoing adaptation processes. Proteasome forms have different substrate preferences and generate specific sets of peptides. In fact, the significance of the spectrum of produced peptides could be underestimated. It may be important not only for the antigen presentation, but for the regulation of multiply intercellular events and even for cellular communication (Ferro et al., 2014). This article describes proteasome diversity in mammalian cells and discusses its biological meaning.

2. Main text

2.1. 20S proteasome

All cellular proteasomes are either 20S proteasomes or contain it as a principal part. The 20S proteasome (20S core particle) is a 700 kDa barrel-like hollow structure with dimensions 115 to 150 Å, composed of four stacked heptameric rings (Groll et al., 1997). Two outer rings are built of seven alpha subunits (α1-α7), while the two inner rings — of beta subunits β1-β7 (Groll et al., 1997; Livneh et al., 2016). Alpha subunits perform scaffolding function and prevent haphazard substrate entry into the proteasome. Their N-termini form «gates» that sequester proteasome interior, where protein degradation is performed by the beta subunits, three of which display proteolytic activities and cleave substrates via N-terminal threonine hydrolase-based mechanism (Groll et al., 1997).

20S proteasomes can differ by subunit composition; this might be considered as a first level of proteasome organization (Fig. 1). Different catalytic beta subunits within the 20S complex usually define major forms or subpopulations (Dahlmann, 2016) of 20S proteasomes (Supplementary Table).

Constitutive (standard, sP) 20S proteasome contain two β1 (Y) subunits, which has caspase-like, activity and perform cleavage after acidic amino acids, two β2 (Z) subunits, demonstrating trypsin-like activity (cleavage after basic amino acids), and two β5 (X) subunits with chymotrypsin-like activity (cleavage after hydrophobic residues) (Livneh et al., 2016). SPs constitute the basis of the proteasome pool in most cells of the body (Supplementary Table).

Immune cells, medullary thymic epithelial cells permanently and many other cells under conditions of oxidative stress, inflammation, cytokine stimulation, viral or bacterial infection assemble so-called immunoproteasomes (iPs). IPs contain pairs of IFN-γ-inducible catalytic (“immune”) subunits β1i (LMP2), β2i (MECL-1) and β5i (LMP7) instead of β1, β2, β5, respectively (Ferrington and Gregerson, 2012).
Not all iPs contain entire set of immune subunits and proteasomes bearing immune and constitutive catalytic subunits simultaneously exist (Guillaume et al., 2010). These are intermediate proteasomes (intPs).

It should be noted that intPs are present in normal conditions in various cells and tissues, including liver, heart and kidney (Supplementary Table). IntPs contain combinations of paired immune and constitutive beta-subunits, thus six types of intermediate 20S complexes can be theoretically formed. The presence of two major types is well established. The first type contains $2\beta1i/2\beta2i/2\beta5$ catalytic subunit set and the second type $2\beta1i/2\beta2/2\beta5i$ (Guillaume et al., 2010). Since each 20S proteasome contain two copies of single beta subunit, combinations with one constitutive and one immune cannot be excluded. Indeed, $\beta1$ and $\beta1i$ were found in the same 20S complexes isolated from IFN-$\gamma$ stimulated HeLa cells (Klare et al., 2007).
addition, proteasomes containing β5 and β5i subunits simultaneously were detected in IFN-β-treated mouse insulinoma cells (Freudenburg et al., 2013). Accordingly, existence of 13 different subtypes of intermediate 20S proteasomes was proposed (Klare et al., 2007). Although, some of these subtypes are unlikely to be formed or maybe detected only in specific conditions, this creates another sublevel of 20S proteasome organization — **asymmetrical 20S proteasomes**.

It should be emphasized that there are forms of proteasomes specific for a particular tissue (Kniepert and Groettrup, 2014). For example, thymoproteasomes (tPs) are found exclusively in cortical thymic epithelial cells (Murata et al., 2007). These proteasomes contain unique catalytic β5t subunit together with immune subunits β1i and β2i (Murata et al., 2007). Spermatocytes, spermatids and sperm express another tissue-specific form of 20S proteasome — spermatoproteasome (spPs) (Qian et al., 2013; Uechi et al., 2014). The hallmark of these proteasomes is a unique α4s subunit (Supplementary Table). According to Qian et al. spermatoproteasome contain only immune catalytic subunits (Qian et al., 2013), although experimental results presented by the authors and by others (Uechi et al., 2014) indicate presence of constitutive beta subunits in the α4s-containing proteasomes.

Incorporation of immune subunits or β5t affects proteasome activity and a repertoire of peptides generated by proteasomes. In contrast to β1, β1i subunit displays rather chymotrypsin-like activity and structural data indicates that β5i “prefers” to cleave after different hydrophobic residues than β5 (Huber et al., 2012). Conversely, the β5t subunit demonstrates 60–70% reduced cleavage after hydrophobic residues comparing to β5 (Murata et al., 2007) and tPs produce a set of unique peptides comparing with iPs (Sasaki et al., 2015). At the same time, recent study by Mishto et al. demonstrated that iPs and constitutive proteasomes generate identical peptides, however the frequency of specific cleavage-site usage might change significantly between these forms of proteasomes (Mishto et al., 2014). Taken together, it can be deduced that all the above-mentioned forms of 20S proteasomes containing various combinations of catalytic subunits, display altering proteolytic activity and produce peptide sets that differ quantitatively, but also in at least some cases — qualitatively (Guillaume et al., 2010; Kincaid et al., 2011; Mishto et al., 2014; Sasaki et al., 2015; Toes et al., 2001). Since quantitative differences are frequently determinative in biological systems and for the sake of simplicity, we will further refer peptide sets produced by different 20S proteasome forms as altered. In addition, presence of different beta subunits, as well as α4s, likely, influences interactions of 20S proteasomes with regulators (Fabre et al., 2015; Qian et al., 2013).

### 2.2. Proteasome regulators

Besides “free” 20S proteasomes there are 20S proteasomes with attached regulator/s. Among those there are activators. Reversible attachment of activators to either one or
both alpha-subunit rings of 20S proteasomes is another level of proteasome organization, that contributes to overall heterogeneity and functionality of proteasomes (Fig. 1, Supplementary Table). In fact, bound activators increase the proteolytic activity of the 20S proteasome via promoting alpha-gate opening and influence substrate specificity of the complex. Several proteasome activators are briefly described below.

The 19S proteasome activator (RP/PA700) is a ~150–160 Å high and ~180–200 Å wide protein complex with MW ~700 kDa, composed of at least 19 subunits (Huang et al., 2016; Liu and Jacobson, 2013). The 19S regulator is a sole regulator that binds ubiquitinated proteins, deubiquitinates, unfolds and translocates them into the activated 20S proteasome for degradation (Liu and Jacobson, 2013). The 20S proteasomes with one or two attached 19S regulators are both frequently termed “26S proteasomes”.

The 11Sαβ activator (PA28αβ, REGαβ) is a 60 to 90 Å heteroheptamer composed of four alpha and three beta subunits, each having MW of ~28 kDa (Huber and Groll, 2017). When the activator is bound to the 20S proteasome, it increases all catalytic activities of the latter. The 11Sαβ is found predominantly in the cytoplasm. The activator is assumed to facilitate cleavage of peptides, rather than proteins (Cascio, 2014) and increase double cleavages of the polypeptide substrates (Dick et al., 1996). However, recent findings indicated that it stimulates degradation of oxidized proteins (Pickering and Davies, 2012). Expression of 11Sαβ is induced by IFN-γ and up-regulated in the immune cells and tissues (Cascio, 2014). Interestingly, 11Sαβ is frequently associated with iPSCs and is engaged in antigen presentation (de Graaf et al., 2011; Fabre et al., 2015; Raule et al., 2014).

The 11Sγ activator (PA28γ, REGγ) is a homoheptamer. It is composed of identical 29.5 kDa subunits and has predominant nuclear localization (Mao et al., 2008). 11Sγ was shown to increase exclusively the trypsin-like activity of the 20S proteasome (Gao et al., 2004) and facilitate ubiquitin and ATP-independent hydrolysis of several regulatory proteins, as well as of oxidized proteins (Pickering and Davies, 2012).

PA200 is another proteasome activator with nuclear localization. It is a monomeric 200 kDa phosphoprotein that forms a hollow, asymmetric dome-like structure of about ~100 × 60 Å (Ortega et al., 2005; Savulescu and Glickman, 2011). In vitro it increases all 20S proteasome catalytic activities, but mainly — the caspase-like activity. PA200 was assumed to stimulate degradation of peptides rather than entire proteins (Ustrell et al., 2002). Though, it was shown to promote ATP- and ubiquitin-independent degradation of acetylated histones during spermatogenesis and in the course of DNA damage repair in somatic cells (Qian et al., 2013).
The 20S proteasomes can bind activators to both alpha-rings and hence, complexes bearing one activator, two identical, or two different activators can be formed (Fig. 1). The latter represent hybrid proteasomes. To date, hybrid proteasomes with 19S-20S-11Sα/β, 19S-20S-11Sγ and 19S-20S-PA200 architecture have been described (Blickwedehl et al., 2008; Bochmann et al., 2014; Hendil et al., 1998; Ustrell et al., 2002).

Besides activators proteasomes interact with hundreds of other proteins (Fabre et al., 2015). Some of these proteins were shown to regulate proteasome function and thus, can be also considered as proteasome regulators. Among them: PI31—a putative proteasome inhibitor (McCutchen-Maloney et al., 2000); Usp14, Uch37 a deubiquitinating enzymes and a ubiquitin ligase Ube3c, these three represent 19S complex subunits that temporarily associate with the activator (Kuo and Goldberg, 2017; Leggett et al., 2002); and Ecm29 (Leggett et al., 2002) (Fig. 1, Supplementary Table).

Mutations in proteasome subunits, as well as post-translational modifications (PTMs) of proteasome subunits and regulators additionally contribute to the proteasome diversity (Fig. 1) (Dahlmann, 2016; Hirano et al., 2016). Most frequent PTMs are: phosphorylation, ubiquitination, SUMOylation, N-acetylation, myristylation, glycosylation, poly-ADP ribosylation, carbonylation, nitration, glycoxidation as well as modification with lipid peroxidation products (Fig. 1) (Guo et al., 2017; Hirano et al., 2016; Hohn and Grune, 2014; Xu et al., 2009). Such modifications affect proteasome assembly, stability, activity, interactions with other proteins and substrates, localization, and sensitivity to proteasome inhibitors (Gohlke et al., 2014; Guo et al., 2016; Hohn and Grune, 2014; Jarome et al., 2013; Kloss et al., 2010; Lokireddy et al., 2015; VerPlank and Goldberg, 2017; D. Wang et al., 2013; Xu et al., 2009). Assuming various PTMs of proteasome subunits, it was predicted that 5 × 10^{15} subtypes of only 20S proteasomes can be theoretically found (X. Wang et al., 2011). However, such estimations are almost impossible to confirm experimentally.

### 2.3. Implications of proteasome diversity

Why the world of proteasomes is so diverse? Currently there are several clues.

First, proteasomes with different regulators have diverse substrate specificities. Indeed, proteins destined for degradation and tagged with ubiquitin can be specifically recognized, unfolded and broken down only by proteasomes with the 19S regulator. In addition, 26S proteasomes can degrade certain proteins even without ubiquitination (Baugh et al., 2009). Interestingly, 26S complexes lacking Usp14 perform hydrolysis of such substrates more efficiently, comparing to the proteasomes with the attached enzyme (H. T. Kim and Goldberg, 2017).
At the same time, the main function of “free” 20S proteasomes is supposed to be the degradation of oxidized, damaged proteins, and of native proteins with intrinsically disordered regions (Baugh et al., 2009; Ben-Nissan and Sharon, 2014; Raynes et al., 2016). This has critical implications for maintenance of normal cellular metabolism and for adaptation to various stresses.

The 11Sαβ and 11Sγ regulators additionally facilitate hydrolysis of oxidized proteins by the 20S proteasomes (Pickering and Davies, 2012). Furthermore, binding of 11Sγ and PA200 promotes ubiquitin-independent hydrolysis of several regulatory proteins and acetylated histones, respectively (Qian et al., 2013) (Supplementary Table).

It should be emphasized that different substrates also differently affect functional state and structure of proteasomes. For instance, ubiquitinated but not non-ubiquitinated proteins were shown to stimulate association of 26S proteasomes with Usp14 and Ube3c, which in the presence of attached ubiquitin-conjugates induce conformational changes of the proteasome, increase its activity and processivity (Huang et al., 2016; Kuo and Goldberg, 2017; Matyskiela et al., 2013; Peth et al., 2009). However, the same substrate can mediate opposite effects on different forms of the proteasomes (Morozov et al., 2016, 2017).

Second, having different activity profiles and cleavage preferences different 20S proteasome forms generate altered peptide repertoires (Guillaume et al., 2010; Kincaid et al., 2011; Mishto et al., 2014; Sasaki et al., 2015; Toes et al., 2001), which are broadened by regulators such as 19S and 11Sαβ (de Graaf et al., 2011; Emmerich et al., 2000; Raule et al., 2014). This is highly relevant for antigen presentation (Fig. 2) (Vigneron and Van den Eynde, 2014). Through enhanced generation of peptides with hydrophobic C-terminus, due to elevated chymotrypsin-like activity, iPs and likely intermediate proteasomes produce peptides compatible with major histocompatibility complex class I (MHC I) more efficiently than constitutive 20S proteasomes (Kincaid et al., 2011; Mishto et al., 2014; Toes et al., 2001). Moreover, different 20S proteasomes contribute to the immune recognition through altered production of spliced peptides (peptides generated from non-sequential residues of the same protein) (Dalet et al., 2011), which can constitute up to a quarter of presented epitopes (Liepe et al., 2016; Vigneron et al., 2004). Concordantly, iPs and intermediate proteasomes are abundant in immune cells (Guillaume et al., 2010) and elevated in nonimmune cells during inflammation (Ferrington and Gregerson, 2012) (Supplementary Table). Another example is unique low affinity T cell receptor ligands produced by thymoproteasomes that are optimal for the positive selection of T cells (Sasaki et al., 2015) and it is noteworthy that the tPs eventually determine the functional state of the mature lymphocytes (Takada et al., 2015). While thymoproteasomes are not found elsewhere except thymus, high amounts of tPs and especially intPs revealed in various nonimmune cells in normal conditions (Guillaume et al., 2010) are not fully understood. Thus, other roles of different proteasomes in cell metabolism cannot be excluded.
Along these lines, the 20S proteasomes were demonstrated to perform incomplete proteolysis and generate stable protein products from precursor-protein. These products might have important biological activity, for example: eIF3a and eIF4G subunits of translation initiation factors (Baugh and Pilipenko, 2004), p50 (NF-κB).
family member), Δ40p53 (Moorthy et al., 2006; Olshina et al., 2018; Solomon et al., 2017) (Fig. 2). Generation of a 30 kDa fragment from Hsp70 following incubation with 20S proteasome was observed (Morozov et al., 2017). The functional activity of this fragment is unknown. However, considering data reported in (Baugh et al., 2009), more examples of stable incompletely processed proteins can be expected and it cannot be ruled out that structural differences of 20S subpopulations affect the size and efficacy of generation of such functional cleavage products, as well as overall substrate turnover rates. Indeed, decreased levels of NF-κB p50 subunits were observed in β5i-deficient cells (Opitz et al., 2011). On the other hand, 26S proteasomes with immune 20S cores were demonstrated to be more efficient in degradation of ubiquitinated substrates than standard 26S complexes (Ebstein et al., 2013; Seifert et al., 2010). Although there is a certain contradiction between these results with data reported by Nathan et al. (2013), Ips were shown to degrade certain substrates faster than constitutive proteasomes in a more recent study (Mishto et al., 2014). Interestingly, different processing rates of several transcription factors by constitutive and iPs were discussed as a possible reason to explain altered expression of 8104 genes in dendritic cells with knocked out immunoproteasome subunits (de Verteuil et al., 2014). Indeed, Ips are involved in several important biological processes including: survival and expansion of T cells (Moebius et al., 2010); maintenance of normal retinal function (Hussong et al., 2011) and pluripotency of human embryonic stem cells (Atkinson et al., 2012); skeletal muscle differentiation (Cui et al., 2014) and cytokine production (Muchamuel et al., 2009). Moreover, iPs facilitate degradation of oxidized proteins and maintain cellular homeostasis during stress (Pickering et al., 2010; Yun et al., 2016). Recent study by St-Pierre and coauthors highlight the role of Ips in adaptation of medullary thymic epithelial cells characterized by high levels of protein synthesis to proteotoxic stress (St-Pierre et al., 2017). In addition, Ips were proposed to be involved in production of peptides which participate in cell-cell interactions in order to maintain nervous system plasticity in mice lacking β2-microglobulin (Lyupina et al., 2013).

Concordantly, an exciting role of 20S proteasomes was recently revealed in neurons (Ramachandran and Margolis, 2017). It has been shown that 40% of 20S proteasomes in mouse neurons are tightly associated with plasma membrane (neuronal membrane proteasomes (NMPs)) and are exposed to the extracellular space (Ramachandran and Margolis, 2017) (Fig. 2). NMPs are capable to degrade intracellular proteins and directly release generated peptides into the extracellular space. By this they regulate target-neuron function through induction of calcium signaling with the involvement of NMDA receptors. Hence, these 20S proteasomes mediate crosstalk between neurons (Ramachandran and Margolis, 2017). Interestingly, a fraction of the NMPs was represented by iPs or at least intermediate proteasomes (Ramachandran and Margolis, 2017). Thus, proteasome form diversity can contribute to the spectrum and quantity of bioactive peptides produced by
**NMPs, mediating potentially differing signals.** At the same time many issues regarding NMPs remain unresolved. What peptides are generated by NMP? Which intracellular proteins they are deriving from? Do these proteins represent entire cellular proteome or a particular population? How different stresses affect presence and function of membrane-integrated proteasomes? What kind of proteasomes with β5i (intermediate, iPs, or both) are associated with neuronal membranes? Do these and constitutive proteasomes mediate different effects on target neurons via generated peptides? And vice versa, could these proteasomes degrade extracellular proteins and release bioactive peptides into the cytosol?

In fact, peptide-signals produced by different proteasomes can also have biological activity inside the cells (Fig. 2). Current concept implies that most of the generated peptides should be immediately degraded by peptidases (Reits et al., 2003), with the rare exception (less than 1%) of those that are eventually exposed on a membrane in complexes with MHCI (Yewdell, 2003). However, hundreds of relatively stable intracellular peptides were reported in different cells (Ferro et al., 2014; Fricker et al., 2012; Gelman et al., 2011). Many of these peptides are not produced from most abundant or least stable proteins, indicating that their generation might not be haphazard (Gelman et al., 2011). These peptides can participate in: modulation of signal transduction, protein-protein interactions, regulation of enzyme function, protein targeting and stability, stress response, host defense from pathogens (Ferro et al., 2014; Russo et al., 2012). Thus, it is reasonable that proteasome diversity contributes to the spectrum and quantity of bioactive intracellular peptides. Currently, however, there are very few described examples and we need more proofs of biological effects mediated by stable peptides generated by different proteasomes. Nevertheless, a peptide deriving from Rpt2 subunit of 19S regulator was found significantly increased in lysates of IFN-γ treated HeLa cells. It was predicted to be generated by iPs. The peptide was shown to stimulate proteasome activity in cellular lysates and potentiate β5i subunit expression in conditions of IFN-γ stimulation (Monte et al., 2017). Interestingly, several other UPS proteins were proposed as sources of bioactive peptides, for instance HECT E3 ubiquitin ligases (Candido-Ferreira et al., 2016) and ubiquitin, fragments of latter possessing antimicrobial activity, were found in amniotic fluid of pregnant women (J. Y. Kim et al., 2007). This indicates that some bioactive peptides are active within cells, while others can function outside. For example, hemopressins which are involved in cellular communication (Gelman et al., 2013). How these peptides are secreted is not clear, since they are produced from cytoplasmic non-secretory proteins. Generation of such peptides by NMPs could be one explanation. Otherwise, peptides may be secreted inside the extracellular vesicles (EVs). These are produced by different cell types and mediate intercellular communication by transporting their cargo to nearby or distant recipient cells inducing various biological effects (Raposo and Stoorvogel, 2013; Ridder et al., 2014, 2015) (Fig. 2). EVs include exosomes formed in cytoplasm, microvesicles that...
directly bud from the cellular membrane and apoptotic bodies. EVs can be constantly produced by cells; however, their release is frequently stimulated by stress and inflammation, or increased in cancer cells. The cargo of vesicles is diverse and is composed of mRNA, miRNA, proteins, peptides and lipids (Raposo and Stoorvogel, 2013). Thus, **bioactive peptides generated by different proteasomes in one cell can be packed into the extracellular vesicles and delivered to another cell** (Fig. 2).

Alternatively, or in addition, bioactive peptides can be produced inside the vesicles, through degradation of cargo proteins. Experimental data favors that some exosomes and microvesicles contain 20S proteasomes and possibly 26S proteasomes (Bochmann et al., 2014; Jia et al., 2017; Lai et al., 2012). These proteasomes are active and their concentration was estimated as 1 ng per 1000—1300 microvesicles (Bochmann et al., 2014). Importantly, proteasomes are not ubiquitous component of the EVs and what determines their presence in the EVs is largely unknown. At the same time EVs, originating from different cells contain different proteasomes: T-cells are secreting largely iPs (Bochmann et al., 2014), mesenchymal stem cells — proteasomes containing both immune and constitutive subunits (Lai et al., 2012), while only standard proteasomes are released from human leukemia K562 cells (Kulichkova et al., 2017). In exosomes from tumor-associated macrophages (TAMs), intermediate proteasomes containing β5i likely reside (Zhu et al., 2015).

The presence of different proteasomes in EVs secreted from different cells probably reflects the major proteasome populations expressed in these cells. Hence, we can speculate that **EVs-mediated intercellular communication can contribute to the bioactive peptide and also a proteasome exchange between cells**. Although direct experimental evidences that exosomal proteasomes can enter a different cell to perform any function are lacking, it was demonstrated that extracellular vesicles can fuse with the membrane of target cells (Prada et al., 2016; Prada and Meldolesi, 2016) and proteasome-containing exosomes are efficiently internalized by the recipient cells (Jia et al., 2017). Along these lines, EVs from bone marrow-derived mesenchymal stem cells were shown to induce resistance of multiply myeloma cells to proteasome inhibitor bortezomib (Wang et al., 2014). Moreover, it was proposed that uptaking of TAM-derived exosomes containing active 20S proteasomes facilitates degradation of denatured or misfolded proteins in recipient cells supporting cell viability in the tumor microenvironment (Zhu et al., 2015). In addition, recent findings indicate that proteasome activity inside the EVs regulate autoimmune response to the EVs cargo proteins and allograft inflammation in mice (Dieude et al., 2015). Another characteristic example: proteasomes in exosomes deriving from hepatitis B virus-replicating cells were reported to modulate cytokine production in recipient monocytes (Jia et al., 2017).

Finally, bioactive peptides and proteasomes can be released from vesicles becoming a source of extracellular proteasomes. These are free floating catalytically active 20S
proteasomes with unknown function found in concentration of 250 ng per ml of human serum (Fig. 2) (Bochmann et al., 2014; Kulichkova et al., 2017; Zoeger et al., 2006). In a recent paper Dianzani et al. demonstrated that these proteasomes are capable to degrade osteopontin, an important pleiotropic cytokine to produce biologically active peptides that stimulate migration of endothelial cells and lymphocytes (Dianzani et al., 2017). It can be expected, and this is proposed by the authors, that different extracellular proteasome forms e.g. iPs or intPs originating from the same or different cells, would produce altered set of osteopontin-derived signaling molecules, mediating different biological effects.

3. Conclusions

Recent investigations of cellular proteasome heterogeneity revealed that different forms of proteasomes can be simultaneously present in a single cell. However, the reasons of such diversity remain obscure. By performing protein hydrolysis different proteasome forms generate specific sets of peptides and proteolysis products. The breadth of biological meaning of this spectrum we are now only beginning to address. Based on the accumulating evidences, we suppose that, along with well established functions, proteasomes may represent modulators of a global signaling network, which rests on the diversity and amount of cleavage products generated by different proteasome forms. This can give additional nontrivial rationale for the elevation of iPs and intPs in healthy tissues and in several pathologies including cancer. All that rises questions concerning a role of a particular proteasome form in various biological processes in healthy and diseased organism. When, and what for it is assembled? Does it generate specific peptides, are these peptides stable and do they have biological function? What is the role of EV-mediated transport of proteasomes? What are the roles of extracellular proteasomes and, since there are different forms of proteasomes outside cells, do they have specific substrates and process them with different efficacy? Besides, putative role of different 20S proteasome forms in regulation of cellular metabolism indicates that special care should be taken when not only broad, but also subunit-specific proteasome inhibitors are used as drugs to treat various pathologies. Future investigations are necessary to answer these challenging questions and to shed more light on the intriguing issue of proteasome diversity.

Declarations

Author contribution statement

All authors listed have significantly contributed to the development and the writing of this article.
**Funding statement**

This work was supported by Russian Science Foundation grant 17-74-30030 and the Program of fundamental research for state academies for 2013–2020 years (№ 01201363822).

**Competing interest statement**

The authors declare no conflict of interest.

**Additional information**

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.heliyon.2018.e00894.

**Acknowledgements**

Authors would like to thank Dr. Vladimir A. Morozov (RKI, Berlin) for important suggestions and comments.

**References**

Atkinson, S.P., Collin, J., Irina, N., Anyfantis, G., Kyung, B.K., Lako, M., Armstrong, L., 2012. A putative role for the immunoproteasome in the maintenance of pluripotency in human embryonic stem cells. Stem Cells 30 (7), 1373–1384.

Baugh, J.M., Pilipenko, E.V., 2004. 20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3. Mol. Cell 16 (4), 575–586.

Baugh, J.M., Viktorova, E.G., Pilipenko, E.V., 2009. Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination. J. Mol. Biol. 386 (3), 814–827.

Ben-Nissan, G., Sharon, M., 2014. Regulating the 20S proteasome ubiquitin-independent degradation pathway. Biomolecules 4 (3), 862–884.

Blickwedehl, J., Agarwal, M., Seong, C., Pandita, R.K., Melendy, T., Sung, P., Bangia, N., 2008. Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. Proc. Natl. Acad. Sci. U. S. A. 105 (42), 16165–16170.

Bochmann, I., Ebstein, F., Lehmann, A., Wohlschlaeger, J., Sixt, S.U., Kloetzl, P.M., Dahlmann, B., 2014. T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes. J. Cell Mol. Med. 18 (1), 59–68.
Candido-Ferreira, I.L., Kronenberger, T., Sayegh, R.S., Batista, I.F., da Silva Junior, P.I., 2016. Evidence of an antimicrobial peptide signature encrypted in HECT E3 ubiquitin ligases. Front. Immunol. 7, 664.

Cascio, P., 2014. PA28alphabeta: the enigmatic magic ring of the proteasome? Biomolecules 4 (2), 566–584.

Cui, Z., Hwang, S.M., Gomes, A.V., 2014. Identification of the immunoproteasome as a novel regulator of skeletal muscle differentiation. Mol. Cell Biol. 34 (1), 96–109.

Dahlmann, B., 2016. Mammalian proteasome subtypes: their diversity in structure and function. Arch. Biochem. Biophys. 591, 132–140.

Dalet, A., Stroobant, V., Vigneron, N., Van den Eynde, B.J., 2011. Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. Eur. J. Immunol. 41 (1), 39–46.

de Graaf, N., van Helden, M.J., Textoris-Taube, K., Chiba, T., Topham, D.J., Kloetzel, P.M., Sijts, A.J., 2011. PA28 and the proteasome immunosubunits play a central and independent role in the production of MHC class I-binding peptides in vivo. Eur. J. Immunol. 41 (4), 926–935.

de Verteuil, D.A., Rouette, A., Hardy, M.P., Lavallee, S., Trofimov, A., Gaucher, E., Perreault, C., 2014. Immunoproteasomes shape the transcriptome and regulate the function of dendritic cells. J. Immunol. 193 (3), 1121–1132.

Dianzani, C., Bellavista, E., Liepe, J., Verderio, C., Martucci, M., Santoro, A., Mishto, M., 2017. Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Sci. Rep. 7, 43718.

Dick, T.P., Ruppert, T., Groettrup, M., Kloetzel, P.M., Kuehn, L., Koszinowski, U.H., Rammensee, H.G., 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86 (2), 253–262.

Dieuleve, M., Bell, C., Turgeon, J., Beillévaire, D., Pomerleau, L., Yang, B., Hebert, M.J., 2015. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci. Transl. Med. 7 (318), 318ra200.

Ehstein, F., Voigt, A., Lange, N., Warnatsch, A., Schroter, F., Prozorovski, T., Kruger, E., 2013. Immunoproteasomes are important for proteostasis in immune responses. Cell 152 (5), 935–937.

Emmerich, N.P., Nussbaum, A.K., Stevanovic, S., Priemer, M., Toes, R.E., Rammensee, H.G., Schild, H., 2000. The human 26 S and 20 S proteasomes
generate overlapping but different sets of peptide fragments from a model protein substrate. J. Biol. Chem. 275 (28), 21140−21148.

Fabre, B., Lambour, T., Garrigues, L., Amalric, F., Vigneron, N., Menneteau, T., Bousquet-Dubouch, M.P., 2015. Deciphering preferential interactions within supramolecular protein complexes: the proteasome case. Mol. Syst. Biol. 11 (1), 771.

Ferrington, D.A., Gregerson, D.S., 2012. Immunoproteasomes: structure, function, and antigen presentation. Prog. Mol. Biol. Transl. Sci. 109, 75−112.

Ferro, E.S., Rioli, V., Castro, L.M., Fricker, L.D., 2014. Intracellular peptides: from discovery to function. EuPA Open Proteomics 3, 143−151.

Freudenburg, W., Gautam, M., Chakraborty, P., James, J., Richards, J., Salvatori, A.S., Skowyra, D., 2013. Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNbeta in mouse pancreatic beta-cells. PLoS One 8 (2), e52408.

Fricker, L.D., Gelman, J.S., Castro, L.M., Gozzo, F.C., Ferro, E.S., 2012. Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides. J. Proteome Res. 11 (3), 1981−1990.

Gao, X., Li, J., Pratt, G., Wilk, S., Rechsteiner, M., 2004. Purification procedures determine the proteasome activation properties of REG gamma (PA28 gamma). Arch. Biochem. Biophys. 425 (2), 158−164.

Gelman, J.S., Dasgupta, S., Bereziuk, I., Fricker, L.D., 2013. Analysis of peptides secreted from cultured mouse brain tissue. Biochim. Biophys. Acta 1834 (11), 2408−2417.

Gelman, J.S., Sironi, J., Castro, L.M., Ferro, E.S., Fricker, L.D., 2011. Peptidomic analysis of human cell lines. J. Proteome Res. 10 (4), 1583−1592.

Gohlke, S., Kloss, A., Tsokos, M., Textoris-Taube, K., Keller, C., Kloetzel, P.M., Dahlmann, B., 2014. Adult human liver contains intermediate-type proteasomes with different enzymatic properties. Ann. Hepatol. 13 (4), 429−438.

Groll, M., Ditzel, L., Lowe, J., Stock, D., Bochtler, M., Bartunik, H.D., Huber, R., 1997. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386 (6624), 463−471.

Guillaume, B., Chapiro, J., Stroobant, V., Colau, D., Van Holle, B., Parvizi, G., Van den Eynde, B.J., 2010. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc. Natl. Acad. Sci. U. S. A. 107 (43), 18599−18604.
Guo, X., Huang, X., Chen, M.J., 2017. Reversible phosphorylation of the 26S proteasome. Protein Cell 8 (4), 255–272.

Guo, X., Wang, X., Wang, Z., Banerjee, S., Yang, J., Huang, L., Dixon, J.E., 2016. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat. Cell Biol. 18 (2), 202–212.

Hendil, K.B., Khan, S., Tanaka, K., 1998. Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem. J. 332 (Pt 3), 749–754.

Hirano, H., Kimura, Y., Kimura, A., 2016. Biological significance of co- and post-translational modifications of the yeast 26S proteasome. J. Proteomics 134, 37–46.

Hohn, T.J., Grune, T., 2014. The proteasome and the degradation of oxidized proteins: part III-Redox regulation of the proteasomal system. Redox Biol. 2, 388–394.

Huang, X., Luan, B., Wu, J., Shi, Y., 2016. An atomic structure of the human 26S proteasome. Nat. Struct. Mol. Biol. 23 (9), 778–785.

Huber, E.M., Basler, M., Schwab, R., Heinemeyer, W., Kirk, C.J., Groettrup, M., Groll, M., 2012. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148 (4), 727–738.

Huber, E.M., Groll, M., 2017. The mammalian proteasome activator PA28 forms an asymmetric alpha4 beta3 complex. Structure 25 (10), 1473–1480 e1473.

Hussong, S.A., Roehrich, H., Kapphahn, R.J., Maldonado, M., Pardue, M.T., Ferrington, D.A., 2011. A novel role for the immunoproteasome in retinal function. Invest. Ophthalmo. Vis. Sci. 52 (2), 714–723.

Jarome, T.J., Kwapis, J.L., Ruenzel, W.L., Helmstetter, F.J., 2013. CaMKII, but not protein kinase A, regulates Rpt6 phosphorylation and proteasome activity during the formation of long-term memories. Front. Behav. Neurosci. 7, 115.

Jia, X., Chen, J., Megger, D.A., Zhang, X., Kozlowski, M., Zhang, L., Yuan, Z., 2017. Label-free proteomic analysis of exosomes derived from inducible hepatitis B virus-replicating HepAD38 cell line. Mol. Cell. Proteomics 16 (4 Suppl. 1), S144–S160.

Kim, H.T., Goldberg, A.L., 2017. The deubiquitinating enzyme Usp14 allosterically inhibits multiple proteasomal activities and ubiquitin-independent proteolysis. J. Biol. Chem. 292 (23), 9830–9839.

Kim, J.Y., Lee, S.Y., Park, S.C., Shin, S.Y., Choi, S.J., Park, Y., Hahm, K.S., 2007. Purification and antimicrobial activity studies of the N-terminal fragment of ubiquitin from human amniotic fluid. Biochim. Biophys. Acta 1774 (9), 1221–1226.
Kincaid, E.Z., Che, J.W., York, I., Escobar, H., Reyes-Vargas, E., Delgado, J.C., Rock, K.L., 2011. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat. Immunol. 13 (2), 129–135.

Klare, N., Seeger, M., Janek, K., Jungblut, P.R., Dahlmann, B., 2007. Intermediate-type 20 S proteasomes in HeLa cells: “asymmetric” subunit composition, diversity and adaptation. J. Mol. Biol. 373 (1), 1–10.

Kloss, A., Meiners, S., Ludwig, A., Dahlmann, B., 2010. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc. Res. 85 (2), 367–375.

Kniepert, A., Groettrup, M., 2014. The unique functions of tissue-specific proteasomes. Trends Biochem. Sci. 39 (1), 17–24.

Kulichkova, V.A., Artamonova, T.O., Lyublinskaya, O.G., Khodorkovskii, M.A., Tomilin, A.N., Tsimokha, A.S., 2017. Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes. Oncotarget 8 (60), 102134–102149.

Kuo, C.L., Goldberg, A.L., 2017. Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc. Natl. Acad. Sci. U. S. A. 114 (17), E3404–E3413.

Lai, R.C., Tan, S.S., Teh, B.J., Sze, S.K., Arslan, F., de Kleijn, D.P., Lim, S.K., 2012. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int. J. Proteomics 2012, 971907.

Leggett, D.S., Hanna, J., Borodovsky, A., Crosas, B., Schmidt, M., Baker, R.T., Finley, D., 2002. Multiple associated proteins regulate proteasome structure and function. Mol. Cell 10 (3), 495–507.

Liepe, J., Marino, F., Sidney, J., Jeko, A., Bunting, D.E., Sette, A., Mishto, M., 2016. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354 (6310), 354–358.

Liu, C.W., Jacobson, A.D., 2013. Functions of the 19S complex in proteasomal degradation. Trends Biochem. Sci. 38 (2), 103–110.

Livneh, I., Cohen-Kaplan, V., Cohen-Rosenzweig, C., Avni, N., Ciechanover, A., 2016. The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Res. 26 (8), 869–885.

Lokireddy, S., Kukushkin, N.V., Goldberg, A.L., 2015. cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the
degradation of misfolded proteins. Proc. Natl. Acad. Sci. U. S. A. 112 (52), E7176–E7185.

Lyupina, Y.V., Bogatyrev, M.E., Orlova, A., Marjukhnich, E.V., Kazansky, D.B., Sharova, N.P., 2013. Proteasomes in the brain of beta2-microglobulin knockout mice. Biochemistry (Mosc) 78 (10), 1124–1133.

Mao, I., Liu, J., Li, X., Luo, H., 2008. REG gamma, a proteasome activator and beyond? Cell. Mol. Life Sci. 65 (24), 3971–3980.

Matyskiela, M.E., Lander, G.C., Martin, A., 2013. Conformational switching of the 26S proteasome enables substrate degradation. Nat. Struct. Mol. Biol. 20 (7), 781–788.

McCutchen-Maloney, S.L., Matsuda, K., Shimbara, N., Binns, D.D., Tanaka, K., Slaughter, C.A., DeMartino, G.N., 2000. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J. Biol. Chem. 275 (24), 18557–18565.

Misho, M., Liepe, J., Textoris-Taube, K., Keller, C., Henklein, P., Weberruss, M., Kloetzl, P.M., 2014. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur. J. Immunol. 44 (12), 3508–3521.

Moebius, J., van den Broek, M., Groettrup, M., Basler, M., 2010. Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur. J. Immunol. 40 (12), 3439–3449.

Monte, E.R., Rossato, C., Llanos, R.P., Russo, L.C., de Castro, L.M., Gozzo, F.C., Rioli, V., 2017. Interferon-gamma activity is potentiated by an intracellular peptide derived from the human 19S ATPase regulatory subunit 4 of the proteasome. J. Proteomics 151, 74–82.

Moorthy, A.K., Savinova, O.V., Ho, J.Q., Wang, V.Y., Vu, D., Ghosh, G., 2006. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. EMBO J. 25 (9), 1945–1956.

Morozov, A., Kulikova, A.A., Astakhova, T.M., Mitkevich, V.A., Burnysheva, K.M., Adzhubei, A.A., Erokhov, P.A., Evgen’ev, M.B., Sharova, N.P., Karpov, V.L., Makarov, A.A., 2016. Amyloid-β increases activity of proteasomes capped with 19S and 11S regulators. J. Alzheimers Dis. 54 (2).

Morozov, A.V., Astakhova, T.M., Garbuz, D.G., Krasnov, G.S., Bobkova, N.V., Zatsepina, O.G., Evgen’ev, M.B., 2017. Interplay between recombinant Hsp70 and proteasomes: proteasome activity modulation and ubiquitin-independent cleavage of Hsp70. Cell Stress Chaperones.
Muchamuel, T., Basler, M., Aujay, M.A., Suzuki, E., Kalim, K.W., Lauer, C., Groettrup, M., 2009. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 15 (7), 781–787.

Murata, S., Sasaki, K., Kishimoto, T., Niwa, S., Hayashi, H., Takahama, Y., Tanaka, K., 2007. Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 316 (5829), 1349–1353.

Nathan, J.A., Spinnenhirn, V., Schmidtke, G., Basler, M., Groettrup, M., Goldberg, A.L., 2013. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152 (5), 1184–1194.

Olshina, M.A., Ben-Nissan, G., Sharon, M., 2018. Functional regulation of proteins by 20S proteasome proteolytic processing. Cell Cycle 17 (4), 393–394.

Opitz, E., Koch, A., Klingel, K., Schmidt, F., Prokop, S., Rahnefeld, A., Voigt, A., 2011. Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis. PLoS Pathog. 7 (9).

Ortega, J., Heymann, J.B., Kajava, A.V., Ustrell, V., Rechsteiner, M., Steven, A.C., 2005. The axial channel of the 20S proteasome opens upon binding of the PA200 activator. J. Mol. Biol. 346 (5), 1221–1227.

Peth, A., Besche, H.C., Goldberg, A.L., 2009. Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol. Cell 36 (5), 794–804.

Pickering, A.M., Davies, K.J., 2012. Differential roles of proteasome and immunoproteasome regulators Pa28alpha beta, Pa28gamma and Pa200 in the degradation of oxidized proteins. Arch. Biochem. Biophys. 523 (2), 181–190.

Pickering, A.M., Koop, A.L., Teoh, C.Y., Ermak, G., Grune, T., Davies, K.J., 2010. The immunoproteasome, the 20S proteasome and the PA28alpha proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem. J. 432 (3), 585–594.

Prada, I., Amin, L., Furlan, R., Legname, G., Verderio, C., Cojoc, D., 2016. A new approach to follow a single extracellular vesicle-cell interaction using optical tweezers. Biotechniques 60 (1), 35–41.

Prada, I., Meldolesi, J., 2016. Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. Int. J. Mol. Sci. 17 (8).

Qian, M.X., Pang, Y., Liu, C.H., Haratake, K., Du, B.Y., Ji, D.Y., Qiu, X.B., 2013. Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis. Cell 153 (5), 1012–1024.
Ramachandran, K.V., Margolis, S.S., 2017. A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function. Nat. Struct. Mol. Biol. 24 (4), 419–430.

Raposo, G., Stoorvogel, W., 2013. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200 (4), 373–383.

Raule, M., Cerruti, F., Benaroudj, N., Migotti, R., Kikuchi, J., Bachi, A., Cascio, P., 2014. PA28alphabeta reduces size and increases hydrophilicity of 20S immunoproteasome peptide products. Chem. Biol. 21 (4), 470–480.

Raynes, R., Pomatto, L.C., Davies, K.J., 2016. Degradation of oxidized proteins by the proteasome: distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. Mol. Aspects Med. 50, 41–55.

Reits, E., Griekspoor, A., Neijssen, J., Groothuis, T., Jalink, K., van Veelen, P., Neefjes, J., 2003. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18 (1), 97–108.

Ridder, K., Keller, S., Dams, M., Rupp, A.K., Schlaudraff, J., Del Turco, D., Momma, S., 2014. Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol. 12 (6), e1001874.

Ridder, K., Sevko, A., Heide, J., Dams, M., Rupp, A.K., Macas, J., Momma, S., 2015. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology 4 (6), e1008371.

Russo, L.C., Asega, A.F., Castro, L.M., Negraes, P.D., Cruz, L., Gozzo, F.C., Ferro, E.S., 2012. Natural intracellular peptides can modulate the interactions of mouse brain proteins and thimet oligopeptidase with 14-3-3 epsilon and calmodulin. Proteomics 12 (17), 2641–2655.

Sasaki, K., Takada, K., Ohte, Y., Kondo, H., Sorimachi, H., Tanaka, K., Murata, S., 2015. Thymoproteasomes produce unique peptide motifs for positive selection of CD8(+) T cells. Nat. Commun. 6, 7484.

Savulescu, A.F., Glickman, M.H., 2011. Proteasome activator 200: the heat is on. Mol. Cell. Proteomics 10 (5), R110.006890.

Seifert, U., Bialy, L.P., Ebstein, F., Bech-Otschir, D., Voigt, A., Schrotter, F., Kruger, E., 2010. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142 (4), 613–624.
Solomon, H., Brauning, B., Fainer, I., Ben-Nissan, G., Rabani, S., Goldfinger, N., Sharon, M., 2017. Post-translational regulation of p53 function through 20S proteasome-mediated cleavage. Cell Death Differ. 24 (12), 2187–2198.

St-Pierre, C., Morgand, E., Benhammadi, M., Rouette, A., Hardy, M.P., Gaboury, L., Perreault, C., 2017. Immunoproteasomes control the homeostasis of medullary thymic epithelial cells by alleviating proteotoxic stress. Cell Rep. 21 (9), 2558–2570.

Takada, K., Van Laethem, F., Xing, Y., Akane, K., Suzuki, H., Murata, S., Takahama, Y., 2015. TCR affinity for thymoproteasome-dependent positively selecting peptides conditions antigen responsiveness in CD8(+) T cells. Nat. Immunol. 16 (10), 1069–1076.

Toes, R.E., Nussbaum, A.K., Degermann, S., Schirle, M., Emmerich, N.P., Kraft, M., Schild, H., 2001. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194 (1), 1–12.

Uechi, H., Hamazaki, J., Murata, S., 2014. Characterization of the testis-specific proteasome subunit alpha4s in mammals. J. Biol. Chem. 289 (18), 12365–12374.

Ustrell, V., Hoffman, L., Pratt, G., Rechsteiner, M., 2002. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J. 21 (13), 3516–3525.

VerPlank, J.J.S., Goldberg, A.L., 2017. Regulating protein breakdown through proteasome phosphorylation. Biochem. J. 474 (19), 3355–3371.

Vigneron, N., Stroobant, V., Chapiro, J., Ooms, A., Degiovanni, G., Morel, S., Van den Eynde, B.J., 2004. An antigenic peptide produced by peptide splicing in the proteasome. Science 304 (5670), 587–590.

Vigneron, N., Van den Eynde, B.J., 2014. Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules 4 (4), 994–1025.

Wang, D., Fang, C., Zong, N.C., Liem, D.A., Cadeiras, M., Scruggs, S.B., Ping, P., 2013. Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human. Mol. Cell. Proteomics 12 (12), 3793–3802.

Wang, J., Hendrix, A., Hermot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., Menu, E., 2014. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 124 (4), 555–566.

Wang, X., Zhao, Z., Luo, Y., Chen, G., Li, Z., 2011. Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines. Proteomics Clin. Appl. 5 (9–10), 484–492.
Xu, J., Wang, S., Wu, Y., Song, P., Zou, M.H., 2009. Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension. Hypertension 54 (3), 625–632.

Yewdell, J.W., 2003. Immunology. Hide and seek in the peptidome. Science 301 (5638), 1334–1335.

Yun, Y.S., Kim, K.H., Tschida, B., Sachs, Z., Noble-Orcutt, K.E., Moriarity, B.S., Kim, D.H., 2016. mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress. Mol. Cell 61 (4), 625–639.

Zhu, Y., Chen, X., Pan, Q., Wang, Y., Su, S., Jiang, C., Liu, S., 2015. A comprehensive proteomics analysis reveals a secretory path- and status-dependent signature of exosomes released from tumor-associated macrophages. J. Proteome Res. 14 (10), 4319–4331.

Zoeger, A., Blau, M., Egerer, K., Feist, E., Dahlmann, B., 2006. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin. Chem. 52 (11), 2079–2086.